Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127451141 | 12745114 | 1 | I | 20100215 | 20150710 | 20160915 | 20160915 | EXP | US-ROCHE-1670301 | ROCHE | 60.00 | YR | F | Y | 0.00000 | 20160915 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127451141 | 12745114 | 1 | PS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | (CYCLE 28 DAYS) OVER 30 TO 90 MINUTES ON DAYS 1 AND 15 | U | 125085 | 10 | MG/KG | SOLUTION FOR INFUSION | ||||||
| 127451141 | 12745114 | 2 | SS | Bevacizumab | BEVACIZUMAB | 1 | U | 125085 | |||||||||||
| 127451141 | 12745114 | 3 | SS | Bevacizumab | BEVACIZUMAB | 1 | U | 125085 | |||||||||||
| 127451141 | 12745114 | 4 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | ON DAYS 1, 8, 15 AND 22 | U | 0 | 25 | MG | |||||||
| 127451141 | 12745114 | 5 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | U | 0 | |||||||||||
| 127451141 | 12745114 | 6 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | U | 0 | |||||||||||
| 127451141 | 12745114 | 7 | SS | COUMADIN | WARFARIN SODIUM | 1 | Unknown | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127451141 | 12745114 | 1 | Carcinoid tumour |
| 127451141 | 12745114 | 2 | Hepatocellular carcinoma |
| 127451141 | 12745114 | 3 | Malignant neoplasm of islets of Langerhans |
| 127451141 | 12745114 | 4 | Carcinoid tumour |
| 127451141 | 12745114 | 5 | Hepatocellular carcinoma |
| 127451141 | 12745114 | 6 | Malignant neoplasm of islets of Langerhans |
| 127451141 | 12745114 | 7 | Carcinoid tumour |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127451141 | 12745114 | HO |
| 127451141 | 12745114 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127451141 | 12745114 | Abdominal pain | |
| 127451141 | 12745114 | Activated partial thromboplastin time prolonged | |
| 127451141 | 12745114 | Blood bilirubin increased | |
| 127451141 | 12745114 | Hypophosphataemia | |
| 127451141 | 12745114 | International normalised ratio increased | |
| 127451141 | 12745114 | Lymphocyte count decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127451141 | 12745114 | 1 | 20100118 | 0 | ||
| 127451141 | 12745114 | 4 | 20100118 | 0 |